Adamis Pharmaceuticals Doses First Patients in Phase 2/3 Clinical Trial for Tempol in the Treatment of COVID-19

NEXT STORY
Pliant Therapeutics to Participate in Upcoming Investor Conferences
PREV STORY
The Worldwide In Vitro Diagnostic Tests Market Research 2021: This 1,500+ Page Report Provides Reliable Estimates and Real-World Forecasts
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

cCARE Wins Jury Trial Against Former CEO/President Dr. Michael J. Moffett

FRESNO, Calif., Feb. 26, 2016 (GLOBE NEWSWIRE) -- A jury in a civil trial ...

author_avatar
NASDAQ Market News

Symphony Health Launches New Long Term Care Channel Offering

CONSHOHOCKEN, Pa., Nov. 30, 2017 (GLOBE NEWSWIRE) -- Symphony Health, a PRA Health Sciences ...

author_avatar
NASDAQ Market News

Pieris Pharmaceuticals to Present at the 2018 Wedbush PacGrow Healthcare Conference

BOSTON, Aug. 08, 2018 (GLOBE NEWSWIRE) -- Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a biotechnology company advancing novel ...

author_avatar
NASDAQ Market News